[AF] Migrasin dudas

[J.D. Carballeira]

Pharmaceutical Research, November 2013
Improving the Stability and Activity of Oral Therapeutic Enzymes—Recent
Advances and Perspectives.
Gregor Fuhrmann, Jean-Christophe Leroux

Abstract


Exogenous, orally-administered enzymes are currently in clinical use or
under development for the treatment of pathologies, such as celiac disease
and phenylketonuria. However, the administration of therapeutic enzymes
*via* the oral route remains challenging due to potential inactivation of
these fragile macromolecular entities in the harsh environment of the
gastrointestinal tract. Enzymes are particularly sensitive because both
proteolysis and unfolding can lead to their inactivation. Current efforts
to overcome these shortcomings involve the application of gastro-resistant
delivery systems and the modification of enzyme structures by polymer
conjugation or protein engineering. This perspective manuscript reviews and
critically discusses recent progress in the oral delivery of therapeutic
enzymes, whose substrate is localized in the gastrointestinal tract.


http://link.springer.com/article/10.1007/s11095-013-1233-y (se puede ver un
preview)


Saludos,

J.D. Carballeira


> 2013/12/23 Mariano Madurga
>
> Tomado de la Ficha técnica de VARIDASA:
>
> 5.2. Propiedades farmacocinéticas